Evidence map›Paper›PMID 24504793›Full record

ReviewArthritis & rheumatology (Hoboken, N.J.)2014

Review: The interleukin-23/interleukin-17 axis in spondyloarthritis pathogenesis: Th17 and beyond.

Judith A Smith, Robert A Colbert

Registry-linked trialAbstract readReview
In one paragraph

Review in Arthritis & rheumatology (Hoboken, N.J.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06114407 (Baricitinib in the Treatment of Refractory Axial Spondyloarthritis Patients), which is not on this map. Cited by 127 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
127citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06114407 phase2unknown statusnot on this mapstarted 2023, after this paper: background citation

Baricitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Comparison With Tofacitinib

TypeinterventionalSponsorBangabandhu Sheikh Mujib Medical University, Dhaka, BangladeshRan2023 to 2024Enrolled184ConditionsSpondyloarthritis, AxialArmsBaricitinib 2mg, Tofacitinib 5 mg
3 · Its place in the literature

Who cites it

127 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Review
  7. PD1RMD open · 2026
    Article
  8. Interferon-JAK-STAT Axis in Bone Metabolism.Current osteoporosis reports · 2026
    Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Exhaustion-Resistant CD8Immunology · 2025
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

67 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Judith A SmithUniversity of Wisconsin, Madison.
Robert A Colbert

Funding

Pathogenic Mechanisms in SpondyloarthritisZIAAR041184 · NIAMS · NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES · PI COLBERT, ROBERT · 2009 to 2025
$47.6M
Intramural NIH HHS ZIA AR041184NIAMS NIH HHS Z01-AR-041184
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsDisease ManagementDisease Models, AnimalHumansInterleukin-17Interleukin-23Signal TransductionSpondylarthritisTh17 CellsInterleukin-17Interleukin-23

Identifiers

PMID24504793
PMCPMC4058712

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.